Sandoz to Acquire Evotec’s Biologics Unit for $300 Million Expansion
Switzerland-headquartered Sandoz (SWX: SDZ) announced that it has signed a non-binding term sheet with Germany’s...
Zhaoke Ophthalmology’s Melphalan Granted FDA Orphan Drug Designation for Pediatric Retinoblastoma
China-based Zhaoke Ophthalmology Ltd (HKG: 6622), a leader in ophthalmic solutions, today announced that its...
Zhaoke Ophthalmology Partners with French FAREVA for Strategic Expansion
China-based Zhaoke Ophthalmology (HKG: 6622) announced the signing of a Memorandum of Agreement (MOA) with...
Lee’s Pharma Partners with Shaohe Biotech to Translate Probiotics into Public Health Solutions
China-based Lee’s Pharmaceutical Holdings Ltd. (HKG: 0950) announced on July 28, 2025, that it has...
GSK Reports 6% Sales Growth in Q2 2025, Driven by Specialty Medicine and Vaccines
UK-based GlaxoSmithKline (GSK; NYSE: GSK) released its Q2 and H1 2025 financial results. Q2 sales...
CSPC Signs Exclusive Licensing Deal with Madrigal for GLP-1 Agonist SYH2086
China-based CSPC Pharmaceutical Group Limited (HKG: 1093) announced today that it has entered into an...
HRAIN Biotech’s HICARA Approved by NMPA for Relapsed/Refractory LBCL
The National Medical Products Administration (NMPA) officially approved the New Drug Application (NDA) for lenecabtagene...
Eli Lilly’s Jaypirca Achieves Primary Endpoint in Phase III BRUIN CLL-314 Trial
US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) announced on July 29, 2025, that...
Shanghai Pharmaceuticals’ B019 Injection Approved for SLE Clinical Trials
Shanghai Pharmaceuticals Holding Co., Ltd’s (SPH, HKG: 2607, SHA: 601607) announced that it has received...
Bayer’s Sevabertinib Granted Priority Review by China’s NMPA for NSCLC Treatment
German pharmaceutical giant Bayer AG (ETR: BAYN) announced on July 28, 2025, that the marketing...
LTZ Therapeutics and Eli Lilly Partner to Develop Myeloid Engager Therapeutics
LTZ Therapeutics and Eli Lilly (NYSE: LLY) announced a significant strategic collaboration on July 29,...
Huadong Medicine Receives NMPA Approval for Phase III Trial of Psoriasis Cream MC2-01
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received approval from the...
China Medical System’s ZUNVEYL NDA Accepted by China’s NMPA for Alzheimer’s Treatment
China Medical System Holdings Ltd (CMS; HKG: 0867, SGX: 8A8) announced on July 28, 2025,...
MSD’s Q2 Earnings Hit by Gardasil Sales Decline, Keytruda Growth Slows
US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) announced its Q2 2025 financial results,...
Novo Nordisk Shares Plummet 20% as Obesity Drug Competition Intensifies and Full-Year Guidance Lowered
Shares of Denmark-based biopharma giant Novo Nordisk A/S (NYSE: NVO) dipped over 20% during trading...
YolTech’s YOLT-203 Gains Orphan Drug Designation for Primary Hyperoxaluria Type 1 Treatment
China-based YolTech Therapeutics announced that the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products...
Cedicine Biotech’s Umbilical Cord Blood Mononuclear Cell Injection Gains CDE Approval for Clinical Trial
China-based Cedicine Biotechnology announced today that the Center for Drug Evaluation (CDE) of the National...
Alphamab Oncology’s JSKN003 Granted FDA Orphan Drug Designation for Gastric and Gastroesophageal Junction Cancer
China-based Alphamab Oncology (HKG: 9966) announced today that its drug candidate JSKN003 has received Orphan...
Pierre Fabre’s Braftovi Approved in China for BRAF V600E-mutant Metastatic Colorectal Cancer
France-based Pierre Fabre Laboratories announced that Braftovi (encorafenib) in combination with cetuximab has been approved...
Henlius Biotech’s HLX14 Recommended for EU Approval by EMA’s CHMP
China-based Shanghai Henlius Biotech, Inc. (HKG: 2696) announced on July 28, 2025, that the European...